Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | VCAM1 | P19320 | 3/20 | 0.66 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.64 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | AKR1C3 | P42330 | 4/20 | 0.52 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5461068 | 0.81 | MEN1 (0.61) | MEN1KMT2APOLBCYP3A4CYP2C19 | |
| SCHEMBL5473761 | 0.81 | KMT2A (0.70) | MEN1KMT2AVCAM1NPBWR1MCHR1 | |
| SCHEMBL992819 | 0.79 | VCAM1 (1.00) | MEN1KMT2AVCAM1NPBWR1MCHR1 | |
| SCHEMBL20379965 | 0.79 | KMT2A (0.76) | MEN1KMT2APOLBLMNACYP3A4 | |
| SCHEMBL13973167 | 0.78 | VCAM1 (0.58) | MEN1KMT2AVCAM1NPBWR1MCHR1 | |
| SCHEMBL5915341 | 0.77 | KMT2A (0.77) | MEN1KMT2APOLBCYP3A4CYP2C19 | |
| SCHEMBL3622325 | 0.77 | VCAM1 (0.76) | MEN1KMT2APOLBVCAM1NPBWR1 | |
| SCHEMBL2985916 | 0.76 | KMT2A (0.71) | MEN1KMT2AVCAM1NPBWR1MCHR1 | |
| SCHEMBL6448884 | 0.76 | KMT2A (0.69) | MEN1KMT2APOLBCYP3A4CYP2C19 | |
| SCHEMBL6645331 | 0.76 | MEN1 (0.71) | MEN1KMT2APOLBLMNACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070010537-A1 | Fused pyramidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-11 | — | — | US | disclosed |
| US-20070010537-A1 | Fused pyramidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-11 | — | — | US | disclosed |
| EP-1657238-A1 | FUSED PYRIMIDINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2006-05-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010537-A1 | Fused pyramidine derivative and use thereof | NR5A1, GNRHR, RXFP3 | MEN1 1223/4885KMT2A 1132/4885POLB 3320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.